SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.

doi:10.1126/scitranslmed.adj7685

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.

Science translational medicine - 15 May 2024

Luk Iris S, Bridgwater Caroline M, Yu Angela, Boila Liberalis D, Yáñez-Bartolomé Mariana, Lampano Aaron E, Hulahan Taylor S, Boukhali Myriam, Kathiresan Meena, Macarulla Teresa, Kenerson Heidi L, Yamamoto Naomi, Sokolov David, Engstrom Ian A, Sullivan Lucas B, Lampe Paul D, Cooper Jonathan A, Yeung Raymond S, Tian Tian V, Haas Wilhelm, Saha Supriya K, Kugel Sita

Abstract excerpt

Intrahepatic cholangiocarcinoma (ICC) is an aggressive bile duct malignancy that frequently exhibits isocitrate dehydrogenase (IDH1/IDH2) mutations. Mutant IDH (IDHm) ICC is dependent on SRC kinase for growth and survival and is hypersensitive to inhibition by dasatinib, but the molecular mechanism underlying this sensitivity is unclear. We found that dasatinib reduced p70 S6 kinase (S6K) and ribosomal protein S6...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Adhesion Molecules

Share to Cholangiocarcinoma

Share to Dasatinib

Share to Guanylate Kinases

Share to Protein Phosphatase 2

Share to Ribosomal Protein S6 Kinases, 70-kDa

Share to src-Family Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 38748774
DOI: 10.1126/scitranslmed.adj7685
PMCID: PMC11218711

Genes

SRC
MAGI1
IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.PMID 38748774Read ↗

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translationSemantic proximity Read ↗

Co-expression of the carbamoyl-phosphate synthase 1 gene and its long non-coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinomaSemantic proximity Read ↗

IDH mutations in liver cell plasticity and biliary cancer.Semantic proximity Read ↗

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.Semantic proximity Read ↗

CLK1 Activates YAP to Promote Intrahepatic CholangiocarcinogenesisSemantic proximity Read ↗

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.Semantic proximity Read ↗

Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1.Semantic proximity Read ↗

Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinomaSemantic proximity Read ↗

Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of actionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.